Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
- 1 May 2001
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 166 (9), 5398-5406
- https://doi.org/10.4049/jimmunol.166.9.5398
Abstract
The mechanism of tumor-associated T cell dysfunction remains an unresolved problem of tumor immunology. Development of T cell defects in tumor-bearing hosts are often associated with increased production of immature myeloid cells. In tumor-bearing mice, these immature myeloid cells are represented by a population of Gr-1+ cells. In this study we investigated an effect of these cells on T cell function. Gr-1+ cells were isolated from MethA sarcoma or C3 tumor-bearing mice using cell sorting. These Gr-1+ cells expressed myeloid cell marker CD11b and MHC class I molecules, but they lacked expression of MHC class II molecules. Tumor-induced Gr-1+ cells did not affect T cell responses to Con A and to a peptide presented by MHC class II. In sharp contrast, Gr-1+ cells completely blocked T cell response to a peptide presented by MHC class I in vitro and in vivo. Block of the specific MHC class I molecules on the surface of Gr-1+ cells completely abrogated the observed effects of these cells. Thus, immature myeloid cells specifically inhibited CD8-mediated Ag-specific T cell response, but not CD4-mediated T cell response. Differentiation of Gr-1+ cells in the presence of growth factors and all-trans retinoic acid completely eliminated inhibitory potential of these cells. This may suggest a new approach to cancer treatment.Keywords
This publication has 26 references indexed in Scilit:
- NITRIC OXIDE AND MACROPHAGE FUNCTIONAnnual Review of Immunology, 1997
- Genetic Immunotherapy of Established Tumors with Adenovirus-Murine Granulocyte-Macrophage Colony-Stimulating FactorHuman Gene Therapy, 1997
- IL-12 and Mutant P53 Peptide-Pulsed Dendritic Cells for the Specific Immunotherapy of CancerJournal of Immunotherapy, 1996
- Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumorsEuropean Journal of Immunology, 1995
- Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor.The Journal of Experimental Medicine, 1994
- Modulation of Growth Factor Receptors on Acute Myeloblastic Leukemia Cells by Retinoic AcidJapanese Journal of Cancer Research, 1994
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Acute Promyelocytic LeukemiaNew England Journal of Medicine, 1993
- Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: Comparative study on BM mononuclear cells and on isolated CD 34+ BM cellsAnnals of Hematology, 1993
- T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of CancerClinical Immunology and Immunopathology, 1993